the present invention relates to compositions that reduce the effective amount of active hsp27 in vivo . exemplary compositions useful in the invention are antisense hsp27 oligonucleotides or rnai nucleotide inhibitors . the invention further relates to the use of these compositions in the treatment of prostate cancer and other cancers that express hsp27 in elevated amounts . as used in the specification and claims of this application , the term “ active hsp27 ” refers to hsp27 which is active as a chaperone to stabilize protein structure at times of stress and in particular inhibits the activity of caspase - 3 , a mediator of apoptosis . reduction in levels of active hsp27 can be achieved by reducing the total amount of hsp27 , either by restricting production of hsp27 or by degrading hsp27 at a rate faster than it is being produced , by converting hsp27 to an inactive form , for example by sequestering hsp27 in an inactive complex such as with an anti - hsp27 antibody . as used in the specification and claims hereof , the cancers which may be treated are those that express hsp27 in an elevated amounts compared to non - cancerous cells of the same tissue type . exemplary cancers include without limitation prostate , bladder , lung , breast , osteosarcoma , pancreatic , colon , melanoma , testicular , colorectal , urothelial , renal cell , hepatocellular , leukemia , lymphoma , and ovarian cancer and central nervous system malignancies . as used in the specification and claims hereof , the term “ sequence specificity ” refers to the existence of a complementary relationship , using watson - crick base pairing , between the oligonucleotide and the hsp27 target that is sufficient to yield specific binding under intra - cellular conditions . perfect complementarity is desirable , but is not absolutely required , particularly where longer oligonucleotides are employed . the sequence of human hsp27 mrna is known , for example from ncbi accession numbers ab020027 , xs4079 , nm — 006308 , nm — 001540 and nm — 001541 . the cdna sequence ( seq . id no . 91 ) forms the basis for the development of antisense oligonucleotides and rnai nucleotide inhibitors . the preferred sequences for antisense , and for rnai are those that target bases in the regions from nucleotides 131 - 161 , 241 - 261 , 361 - 371 , 551 - 580 , 661 - 681 and 744 - 764 in seq . id no . 91 . in order to target bases within these regions , an antisense or rnai molecule must have sequence specificity with a region that includes at least one of the listed bases , preferably at least 10 of the listed bases . suitable antisense oligonucleotides have a length of from 12 to 35 oligonucleotides and have sequence specificity to the hsp27 mrna sequence . antisense oligonucleotides that were made and tested for their ability to reduce the amount of active hsp27 mrna are set forth as seq id nos . 1 to 82 . preferred antisense oligonucleotides have the sequence 5 ′- ggggacgcggcgctcggtcat - 3 ′ ( seq . id no . 81 ) or 5 ′- gggacgcggcgctcggtcat - 3 ′ ( seq . id no . 82 ) which targets the translation initiation site of hsp27 mrna , as well as those with seq . id nos . 25 , 36 , 56 , 57 , 67 and 76 . rna interference or “ rnai ” is a term initially coined by fire and co - workers to describe the observation that double - stranded rna ( dsrna ) can block gene expression when it is introduced into worms ( fire et al . ( 1998 ) nature 391 , 806 - 811 , incorporated herein by reference ), dsrna directs gene - specific , post - transcriptional silencing in many organisms , including vertebrates , and has provided a new tool for studying gene function . rnai involves mrna degradation , but many of the biochemical mechanisms underlying this interference are unknown . the use of rnai has been further described in carthew et al . ( 2001 ) current opinions in cell biology 13 , 244 - 248 , and elbashir et al , ( 2001 ) nature 411 , 494 - 498 , both of which are incorporated herein by reference . the rnai molecules of the invention are double - stranded or single - stranded rna of from about 21 to about 23 nucleotides which mediate rna inhibition . that is , the isolated rnai of the present invention mediate degradation of mrna of the hsp27 gene . the terms rna , rna molecule ( s ), rna segment ( s ) and rna fragment ( s ) may be used interchangeably to refer to rna that mediates rna interference . these terms include double - stranded rna , single - stranded rna , isolated rna ( partially purified rna , essentially pure rna , synthetic rna , recombinantly produced rna ), as well as altered rna that differs from naturally occurring rna by the addition , deletion , substitution and / or alteration of one or more nucleotides . such alterations can include addition of non - nucleotide material , such as to the end ( s ) of the rna or internally ( at one or more nucleotides of the rna ). nucleotides in the rna molecules of the present invention can also comprise non - standard nucleotides , including non - naturally occurring nucleotides or deoxyribonucleotides . collectively , all such altered rnai compounds are referred to as analogs or analogs of naturally - occurring rna . rna of the present invention need only be sufficiently similar to natural rna that it has the ability to mediate rnai . as used herein the phrase “ mediate rnai ” refers to and indicates the ability to distinguish which mrna are to be affected by the rnai machinery or process . rna that mediates rnai interacts with the rnai machinery such that it directs the machinery to degrade particular mrnas or to otherwise reduce the expression of the target protein . in one embodiment , the present invention relates to rna molecules that direct cleavage of specific mrna to which their sequence corresponds . it is not necessary that there be perfect correspondence of the sequences , but the correspondence must be sufficient to enable the rna to direct rnai inhibition by cleavage or lack of expression of the target mrna . as noted above , the rna molecules of the present invention in general comprise an rna portion and some additional portion , for example a deoxyribonucleotide portion . the total number of nucleotides in the rna molecule is suitably less than 49 in order to be effective mediators of rnai . in preferred rna molecules , the number of nucleotides is 16 to 29 , more preferably 18 to 23 , and most preferably 21 - 23 . the rna portion of suitable rnai molecules are set forth in seq . id nos . 83 - 90 . these sequences are the sense rna strand . they may be used in rnai treatment in combination with a corresponding antisense strand . the oligonucleotides employed as antisense or rnai molecules may be modified to increase the stability of the oligonucleotides in vivo . for example , the oligonucleotides may be employed as phosphorothioate derivatives ( replacement of a non - bridging phosphoryl oxygen atoms with a sulfur atom ) which have increased resistance to nuclease digestion . moe modification ( isis backbone ) is also effective . administration of antisense oligonucleotides can be carried out using the various mechanisms known in the art , including naked administration and administration in pharmaceutically acceptable lipid carriers . for example , lipid carriers for antisense delivery are disclosed in u . s . pat . nos . 5 , 855 , 911 and 5 , 417 , 978 which are incorporated herein by reference . in general , the antisense is administered by intravenous , intraperitoneal , subcutaneous or oral routes , or direct local tumor injection . the amount of antisense oligonucleotide or other therapeutic administered is one effective to reduce the amount of active hsp 27 . it will be appreciated that this amount will vary both with the effectiveness of the antisense oligonucleotides or other therapeutic agent employed , and with the nature of any carrier used . the determination of appropriate amounts for any given composition is within the skill in the art , through standard series of tests designed to assess appropriate therapeutic levels . the rnai molecules of the invention are used in therapy to treat patients , including human patients , that have cancers or other diseases of a type where a therapeutic benefit is obtained by the inhibition of expression of the targeted protein . sirna molecules of the invention are administered to patients orally , by one or more daily injections ( intravenous , subcutaneous , intravesical , or intrathecal ) or by continuous intravenous or intrathecal administration for one or more treatment cycles to reach plasma and tissue concentrations suitable for the regulation of the targeted mrna and protein . prostate cancer is one cancer that overexpresses hsp27 in later stage cancers , and in particular in cancers that have become androgen independent . fig9 shows immunoreactivity of hsp27 determined from immunohistological evaluation of hsp27 in an nht tissue array . in the benign samples , immunoreactivity is limited to the basal layer . as the duration of neoadjuvant therapy increases , the immunoreactivity increases , with androgen independent tumors showing very strong reactivity . for treatment of prostate cancer , the therapeutic compositions of the invention are suitably administered after initial of androgen withdrawal . initiation of androgen withdrawal may be accomplished via surgical ( removal of both testicles ) or medical ( drug - induced suppression of testosterone ) castration , which is currently indicated for treatment of prostate cancer . medical castration can be achieved by various regimens , including lhrh agents or antiandrogens . ( cleave et al ., cmaj 160 : 225 - 232 ( 1999 )). intermittent therapy in which reversible androgen withdrawal is effected is described in gleave et al . eur . urol . 34 ( supp . 3 ): 37 - 41 ( 1998 ). the inhibition of hsp 27 expression may be transient , and for treatment of prostate cancer ideally should occur coincident with androgen withdrawal . in humans , this means that inhibition of expression should be effective starting within a day or two of androgen withdrawal ( before or after ) and extending for about 3 to 6 months . this may require multiple doses to accomplish . it will be appreciated , however , that the period of time may be more prolonged , starting before castration and expending for substantial time afterwards without departing from the scope of the invention . the method for treating cancer , including prostate cancer , in accordance with the invention may further include administration of chemotherapy agents and / or additional antisense oligonucleotides directed at different targets . examples of other therapy agents include , without limitation , taxanes ( paclitaxel or docetaxel ), mitoxanthrone , and antisense directed to bcl - 2 , bcl - xl or c - myc . inhibition of hsp27 using antisense or rnai can be used to enhance the activity of like taxanes or gemcitabine , as well as biologic agents for the treatment of prostate , breast , lung , urothelial and other cancers . the invention will now be further described with respect to the following non - limiting examples . example 1 a plurality of antisense compounds as defined in seq . id nos . 1 - 81 were prepared , and each sequence was tested for levels of hsp 27 mrna expression human prostate cancer pc3 cells by northern blot after exposure to 50 nm of a specified antisense oligonucleotide in an oligofectamine carrier . the results of these tests , as a percentage of an oligofectamine only control , for seq . id nos . 1 - 81 are shown in fig1 a - c . as shown , although not all antisense sequences are effective , effective antisense sequences are found throughout the length of the hsp27 mrna . example 2 pc3 prostate cancer cells were transfected at 40 % confluency with three concentrations ( 10 , 30 and 50 nm ) of 6 different hsp27 - antisense oligonucleotides 2 times , successively in 10 cm dishes , using an oligofectamine carrier . rna was extracted 48 hours after the first treatment and analyzed by northern blot . the antisense oligonucleotides tested were those with seq . id nos . 67 , 57 , 25 , 76 , 56 and 36 . as controls , a scrambled oligonucleotide and oligofectamine only experiments were conducted . all of the oligonucleotides tested showed down - regulation of hsp27 with respect to the controls at least at one of the concentrations . seqs . id 71 and 74 appeared to be most effective , with significant down - regulation at 10 nm . the results , relative to a gapdh control are depicted graphically in fig2 . example 3 xenografts of lncap prostate cancer cells were introduced into mice , and the effect of intraperitoneal injection of hsp27 - antisense oligonucleotide ( seq . id no . 82 ) administered intraperitoneally , 10 mg / kg ., once daily for four weeks following androgen withdrawal by castrration was evaluated . as shown in fig3 a and 3b , tumoral volume and serum psa increased in the weeks following treatment with a scrambled control , indicating progression to androgen independence , and thus , the loss of efficacy of the castration therapy . in contrast , this progression to androgen independence was not observed in the same time period when treatment with the hsp27 antisense oligonucleotide was given . example 4 xenografts of pc3 prostate cancer cells were introduced into mice , and the effect of intraperitoneal injection of hsp27 - antisense oligonucleotide ( seq . id no . 82 ) administered intraperitoneally , 10 mg / kg ., once daily for four weeks with and without taxol was evaluated . as shown in fig4 a and 4b , tumor volume was significantly reduced by treatment with hsp27 - antisense , as compared to scrambled oligonucleotide . this effect was enhanced when taxol treatment was combined with the antisense treatment . fig4 a illustrates single agent anti - tumor activity while fig4 b illustrates that administration of hsp27 antisense can sensitize cells to paclitaxel in vivo . the control in 4 b is scrambled plus taxol . example 5 rnai molecules having a sequence in accordance with seq . id nos . 84 , 85 , 87 , 88 and 90 were tested in pc3 cells . the pc cells were transfected with various amounts of the hsp27 sirna or scrambled control . two days after transfection , total rna was extracted and analyzed by northern blotting for hsp27 and 285 levels . cells treated with oligofectimine only were used as an additional control . fig5 shows densitometric measurements of hsp27 mrna after normalization to 28s mrna controls . as shown , seq . id nos . 84 , 85 , 87 , 88 and 90 are all effective to significantly reduce hsp27 expression as compared to the scrambled control . example 6 rnai having a sequence in accordance with seq id . no . 84 was transfected into pc3 cells , and the amount of expressed hsp27 protein , as a compared to vinculin expression was determined . the results are shown in fig6 a and 6b . as shown , a dose dependent reduction in hsp27 expression is observed following treatment with the rnai molecule . example 7 lncap cells ( 10 4 cells / well , cultured in 12 - well plates ) were transfected in vitro with 1 nm rnai having a sequence in accordance with seq id . no . 84 . cell growth was monitored using a crustal violet assay . as shown in fig7 a , the rnai treatment resulted in a reduction in cell growth as compared to treatment with oligofectamine only or a scrambled control . the experiment was repeated using pc3 cells . fig7 shows the % of cells alive 3 days after transfection . fig7 c shows growth inhibition of pc3 cells in vitro after treatment with hsp27 antisense seq , id no . 82 example 8 human bladder cancer t24 cells transfected with hsp27 antisense ( seq . id no 82 ) or rnai ( seq . id no . 84 ) were tested for hsp27 expression . as shown in fig8 , rnai and the antisense were both effective to reduce the amount of hsp27 expressed in these cells .
therapeutic agents which target heat shock protein 27 in vivo are used to provide treatment to individuals , particularly human individuals , suffering from prostate cancer and other cancers that overexpress hsp27 . a therapeutic agent , for example an antisense oligonucleotide or rnai nucleotide inhibitor with sequence specificity for hsp27 mrna , for example human hsp27 mrna , is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount . the therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier , and packaged in dosage unit form . a preferred dosage unit form is an injectable dosage unit form .